Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CODX Co-Diagnostics	$0.33 -1.6%	$0.28	$0.23 ▼ $1.65	$12.70M	0.51	5.27 million shs	264,117 shs
LYRA Lyra Therapeutics	$7.00 -0.7%	$8.17	$3.81 ▼ $37.50	$11.51M	0.16	16,200 shs	6,056 shs
NDRA ENDRA Life Sciences	$4.09 -1.2%	$5.20	$2.90 ▼ $22.68	$3.08M	-0.18	62,852 shs	19,678 shs
XAIR Beyond Air	$2.22 +1.8%	$3.04	$2.02 ▼ $13.52	$11.60M	0.25	179,910 shs	27,412 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CODX Co-Diagnostics	0.00%	+3.39%	+27.49%	+25.84%	-79.00%
LYRA Lyra Therapeutics	0.00%	-4.52%	+4.48%	+49.57%	-56.06%
NDRA ENDRA Life Sciences	0.00%	-6.83%	-22.54%	+18.90%	-71.46%
XAIR Beyond Air	0.00%	-1.33%	-25.50%	-39.61%	-73.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CODX Co-Diagnostics	4.3445 of 5 stars	3.5	5.0	4.4	2.1	0.0	1.3
LYRA Lyra Therapeutics	2.941 of 5 stars	3.0	5.0	0.0	2.1	2.5	0.6
NDRA ENDRA Life Sciences	2.5489 of 5 stars	3.5	4.0	0.0	2.7	0.0	0.6
XAIR Beyond Air	3.9068 of 5 stars	3.8	2.0	3.5	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CODX Co-Diagnostics	3.00	Buy	$5.50	1,568.18% Upside
LYRA Lyra Therapeutics	2.00	Hold	$100.00	1,328.57% Upside
NDRA ENDRA Life Sciences	3.00	Buy	$50.00	1,122.49% Upside
XAIR Beyond Air	3.50	Strong Buy	$11.00	395.50% Upside

Current Analyst Ratings Breakdown

Latest NDRA, LYRA, CODX, and XAIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	XAIR Beyond Air	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00
8/15/2025	CODX Co-Diagnostics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/14/2025	LYRA Lyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
8/13/2025	XAIR Beyond Air	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00
7/17/2025	XAIR Beyond Air	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2025	XAIR Beyond Air	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$11.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CODX Co-Diagnostics	$3.91M	3.25	N/A	N/A	$1.07 per share	0.31
LYRA Lyra Therapeutics	$1.53M	7.50	N/A	N/A	$0.99 per share	7.07
NDRA ENDRA Life Sciences	N/A	N/A	N/A	N/A	$1.96 per share	N/A
XAIR Beyond Air	$3.70M	3.14	N/A	N/A	$1.99 per share	1.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CODX Co-Diagnostics	-$37.64M	-$1.15	N/A	N/A	N/A	-3,588.33%	-69.49%	-60.49%	11/6/2025 (Estimated)
LYRA Lyra Therapeutics	-$93.43M	-$29.01	N/A	N/A	N/A	-5,043.64%	-404.56%	-60.06%	11/11/2025 (Estimated)
NDRA ENDRA Life Sciences	-$11.51M	-$33.89	N/A	N/A	N/A	N/A	-194.14%	-127.89%	N/A
XAIR Beyond Air	-$46.62M	-$11.93	N/A	N/A	N/A	-880.72%	-232.61%	-115.92%	11/10/2025 (Estimated)

Latest NDRA, LYRA, CODX, and XAIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CODX Co-Diagnostics	-$0.25	-$0.23	+$0.02	-$0.23	$0.30 million	$0.16 million
8/14/2025	Q2 2025	NDRA ENDRA Life Sciences	-$2.27	-$1.71	+$0.56	-$1.71	N/A	N/A
8/12/2025	Q2 2025	LYRA Lyra Therapeutics	-$5.79	-$5.51	+$0.28	-$5.51	$0.18 million	$0.29 million
8/12/2025	Q1 2026	XAIR Beyond Air	-$1.50	-$1.53	-$0.03	-$1.53	$1.75 million	$1.76 million
6/17/2025	Q4 2025	XAIR Beyond Air	-$2.80	-$1.80	+$1.00	-$0.09	$1.39 million	$1.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CODX Co-Diagnostics	N/A	N/A	N/A	N/A	N/A
LYRA Lyra Therapeutics	N/A	N/A	N/A	N/A	N/A
NDRA ENDRA Life Sciences	N/A	N/A	N/A	N/A	N/A
XAIR Beyond Air	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CODX Co-Diagnostics	N/A	4.12	3.83
LYRA Lyra Therapeutics	N/A	2.78	2.78
NDRA ENDRA Life Sciences	N/A	3.21	3.21
XAIR Beyond Air	0.92	3.24	2.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CODX Co-Diagnostics	14.99%
LYRA Lyra Therapeutics	95.62%
NDRA ENDRA Life Sciences	1.19%
XAIR Beyond Air	31.50%

Insider Ownership

Company	Insider Ownership
CODX Co-Diagnostics	8.40%
LYRA Lyra Therapeutics	3.25%
NDRA ENDRA Life Sciences	0.04%
XAIR Beyond Air	19.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CODX Co-Diagnostics	100	38.52 million	35.29 million	Optionable
LYRA Lyra Therapeutics	50	1.64 million	1.59 million	Optionable
NDRA ENDRA Life Sciences	20	750,000	753,000	Not Optionable
XAIR Beyond Air	70	5.23 million	4.21 million	Optionable

NDRA, LYRA, CODX, and XAIR Headlines

Recent News About These Companies

Beyond Air (NASDAQ:XAIR) Earns Buy Rating from D. Boral Capital

August 22, 2025 | americanbankingnews.com

Beyond Air, Inc. (NASDAQ:XAIR) Short Interest Update

August 22, 2025 | americanbankingnews.com

Beyond Air, Inc. Expands Global LungFit® PH Distribution Network to 34 Countries

August 20, 2025 | quiverquant.comQ

Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan

August 20, 2025 | globenewswire.com

Beyond Air price target lowered to $5 from $20 at Piper Sandler

August 14, 2025 | msn.com

Beyond Air’s Earnings Call Highlights Growth and Challenges

August 13, 2025 | msn.com

Beyond Air, Inc. (NASDAQ:XAIR) Q1 2026 Earnings Call Transcript

August 13, 2025 | msn.com

Beyond Air Reports Strong Revenue Growth in Q1 2026

August 13, 2025 | msn.com

Beyond Air reports Q1 EPS ($1.53) vs. ($5.32) last year

August 12, 2025 | msn.com

Beyond Air, Inc. (XAIR) Q1 2026 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates

August 12, 2025 | zacks.com

Beyond Air Inc (XAIR) Q1 2026 Earnings Report Preview: What To Expect

August 12, 2025 | finance.yahoo.com

Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast

July 25, 2025 | globenewswire.com

Beyond Air stock surges after securing Premier group purchasing deal

July 22, 2025 | in.investing.com

Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.

July 22, 2025 | globenewswire.com

XAIR | Beyond Air Inc. Annual Cash Flow Statement | MarketWatch

July 19, 2025 | marketwatch.com

D. Boral Capital Initiates Coverage of Beyond Air (XAIR) with Buy Recommendation

July 18, 2025 | msn.com

Beyond Air, Inc. (XAIR) - Yahoo Finance

July 12, 2025 | finance.yahoo.com

Beyond Air Implements Reverse Stock Split for Nasdaq Compliance

July 10, 2025 | tipranks.com

Beyond Air Inc.

June 26, 2025 | barrons.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NDRA, LYRA, CODX, and XAIR Company Descriptions

Co-Diagnostics NASDAQ:CODX

$0.33 -0.01 (-1.58%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$0.33 0.00 (-0.82%)

As of 08/29/2025 07:56 PM Eastern

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Lyra Therapeutics NASDAQ:LYRA

$7.00 -0.05 (-0.71%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$7.04 +0.04 (+0.50%)

As of 08/29/2025 05:12 PM Eastern

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

ENDRA Life Sciences NASDAQ:NDRA

$4.09 -0.05 (-1.21%)

Closing price 08/29/2025 03:55 PM Eastern

Extended Trading

$4.14 +0.05 (+1.12%)

As of 08/29/2025 04:56 PM Eastern

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Beyond Air NASDAQ:XAIR

$2.22 +0.04 (+1.83%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$2.18 -0.04 (-1.80%)

As of 08/29/2025 07:59 PM Eastern

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time